Marcia Morita‐Sherman

Marcia Morita‐Sherman

Auto-generated profile, based on publicly available information

Marcia Morita‐Sherman

Epilepsy Center Cleveland Clinic Foundation Cleveland Ohio USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2020 in Human Brain Mapping
Verified
Journal Article
Open access
PDF file
SSSanjay M. Sisodiya
Sanjay M. Sisodiya
CWChristopher D. Whelan
Christopher D. Whelan
SHSean N. Hatton
Sean N. Hatton
KHKhoa Huynh
Khoa Huynh
AAAndre Altmann
Andre Altmann
EGENIGMA Consortium Epilepsy Working Group
ENIGMA Consortium Epilepsy Working Group
Epilepsy is a common and serious neurological disorder, with many different constituent conditions characterized by their electro clinical, imaging, and genetic features. MRI has been fundamental in advancing our understanding of brain processes in the epilepsies. Smaller‐scale studies have identified many interesting imaging phenomena, with implications both for understanding pathophysiology and improving clinical care. Through the infrastructure and concepts now well‐established by the ENIGMA Consortium, ENIGMA‐Epilepsy was established to strengthen epilepsy neuroscience by greatly increasing sample sizes, leveraging ideas and methods established in other ENIGMA projects, and generating a body of collaborating scientists and clinicians to drive forward robust research. Here we review published, current, and future projects, that include structural MRI, diffusion tensor imaging (DTI), and resting state functional MRI (rsfMRI), and that employ advanced methods including structural covariance, and event‐based modeling analysis. We explore age of onset‐ and duration‐related features, as well as phenomena‐specific work focusing on particular epilepsy syndromes or phenotypes, multimodal analyses focused on understanding the biology of disease progression, and deep learning approaches. We encourage groups who may be interested in participating to make contact to further grow and develop ENIGMA‐Epilepsy.

2 August 2021 in Epilepsia
Verified
Journal Article
Closed access
PDF file
ZFZachary Fitzgerald
Zachary Fitzgerald
MMMarcia Morita‐Sherman
Marcia Morita‐Sherman
OHOlivia Hogue
Olivia Hogue
Boney JosephBoney Joseph
Boney Joseph
MAMarina K. M. Alvim
Marina K. M. Alvim
LJLara Jehi
Lara Jehi

6 April 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SASimoni H. Avansini
Simoni H. Avansini
BLBeatriz Pereira De Sousa Lima
Beatriz Pereira De Sousa Lima
RSRodrigo Secolin
Rodrigo Secolin
MSMarilza L. Santos
Marilza L. Santos
ACAna Carolina Coan
Ana Carolina Coan
Iscia Lopes-CendesIscia Lopes-Cendes
Iscia Lopes-Cendes
Epilepsy is misdiagnosed in up to 25% of patients, leading to serious and long-lasting consequences. Recently, circulating microRNAs have emerged as potential biomarkers in a number of clinical scenarios. The purpose of this study was to identify and to validate circulating microRNAs that could be used as biomarkers in the diagnosis of epilepsy. Quantitative real-time PCR was used to measure plasma levels of three candidate microRNAs in two phases of study: an initial discovery phase with 14 patients with mesial temporal lobe epilepsy (MTLE), 13 with focal cortical dysplasia (FCD) and 16 controls; and a validation cohort constituted of an independent cohort of 65 patients with MTLE and 83 controls. We found hsa-miR-134 downregulated in patients with MTLE (p = 0.018) but not in patients with FCD, when compared to controls. Furthermore, hsa-miR-134 expression could be used to discriminate MTLE patients with an area under the curve (AUC) of 0.75. To further assess the robustness of hsa-miR-134 as a biomarker for MTLE, we studied an independent cohort of 65 patients with MTLE, 27 of whom MTLE patients were responsive to pharmacotherapy, and 38 patients were pharmacoresistant and 83 controls. We confirmed that hsa-miR-134 was significantly downregulated in the plasma of patients with MTLE when compared with controls (p < 0.001). In addition, hsa-miR-134 identified patients with MTLE regardless of their response to pharmacotherapy or the presence of MRI signs of hippocampal sclerosis. We revealed that decreased expression of hsa-miR-134 could be a potential non-invasive biomarker to support the diagnosis of patients with MTLE.

31 July 2021 in Epilepsia
Verified
Journal Article
Closed access
PDF file
MAMarina K. M. Alvim
Marina K. M. Alvim
MMMarcia E. Morita‐Sherman
Marcia E. Morita‐Sherman
UCUniversity lin Campinas
University lin Campinas
NRNatália P. Rocha
Natália P. Rocha
ÉVÉrica L. Vieira
Érica L. Vieira
FCFernando Cendes
Fernando Cendes

1 January 2013 in Frontiers in Neurology
Verified
Journal Article
Open access
ACAna Carolina Coan
Ana Carolina Coan
MMMarcia Elisabete Morita
Marcia Elisabete Morita
BCBrunno Machado de Campos
Brunno Machado de Campos
UCUniversity lin Campinas
University lin Campinas
FCFernando Cendes
Fernando Cendes
Purpose: Patients with mesial temporal lobe epilepsy (MTLE) without MRI abnormalities (MTLE-NL) represent a challenge for definition of underlying pathology and for presurgical evaluation. In a recent study we observed significant amygdala enlargement (AE) in 14% of MTLE patients with MRI signs of hippocampal sclerosis. Areas of gray matter volume (GMV) increase could represent structural abnormalities related to the epileptogenic zone or part of a developmental abnormality. Our objective was to look for undetected areas of increased GMV in MTLE-NL using post processing MRI techniques to better understand the pathophysiology of this condition. Methods: We evaluated 66 patients with MTLE-NL on visual analysis and 82 controls. Voxel-based morphometry (VBM) group analysis was performed with VBM8/SPM8 looking for areas of increased GMV. We then performed automatic amygdala volumetry using FreeSurfer software and T2 relaxometry to confirm VBM findings. Results: Voxel-based morphometry group-analysis demonstrated increased amygdala volume in the MTLE-NL group compared to controls. Individual volumetric analysis confirmed AE in eight (12%) patients. Overall, from all patients with AE and defined epileptic focus, four (57%) had the predominant increased volume ipsilateral to the epileptic focus. These results were cross-validated by a secondary VBM analysis including subgroups of patients according to the volumetric data. T2 relaxometry demonstrated no amygdala hyperintense signal in any individual with significant AE. There were no clinical differences between patients with and without AE. Discussion: This exploratory study demonstrates the occurrence of AE in 12% of patients with MTLE-NL. This finding supports the hypothesis that there might be a subgroup of patients with MTLE-NL in which the enlarged amygdala could be related to the epileptogenic process. Further studies are necessary but this finding could be of great importance in the understanding of MTLE-NL.

26 March 2020 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
SLS. Louis
S. Louis
MMM. Morita-Sherman
M. Morita-Sherman
SJS. Jones
S. Jones
DVD. Vegh
D. Vegh
WBW. Bingaman
W. Bingaman
LJL. Jehi
L. Jehi
BACKGROUND AND PURPOSE: NeuroQuant is an FDA-approved software that performs automated MR imaging quantitative volumetric analysis. This study aimed to compare the accuracy of NeuroQuant analysis with visual MR imaging analysis by neuroradiologists with expertise in epilepsy in identifying hippocampal sclerosis. MATERIALS AND METHODS: We reviewed 144 adult patients who underwent presurgical evaluation for temporal lobe epilepsy. The reference standard for hippocampal sclerosis was defined by having hippocampal sclerosis on pathology (n = 61) or not having hippocampal sclerosis on pathology (n = 83). Sensitivities, specificities, positive predictive values, and negative predictive values were compared between NeuroQuant analysis and visual MR imaging analysis by using a McNemar paired test of proportions and the Bayes theorem. RESULTS: NeuroQuant analysis had a similar specificity to neuroradiologist visual MR imaging analysis (90.4% versus 91.6%; P = .99) but a lower sensitivity (69.0% versus 93.0%, P < .001). The positive predictive value of NeuroQuant analysis was comparable with visual MR imaging analysis (84.0% versus 89.1%), whereas the negative predictive value was not comparable (79.8% versus 95.0%). CONCLUSIONS: Visual MR imaging analysis by a neuroradiologist with expertise in epilepsy had a higher sensitivity than did NeuroQuant analysis, likely due to the inability of NeuroQuant to evaluate changes in hippocampal T2 signal or architecture. Given that there was no significant difference in specificity between NeuroQuant analysis and visual MR imaging analysis, NeuroQuant can be a valuable tool when the results are positive, particularly in centers that lack neuroradiologists with expertise in epilepsy, to help identify and refer candidates for temporal lobe epilepsy resection. In contrast, a negative test could justify a case referral for further evaluation to ensure that false-negatives are detected.